|

Belinostat Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: Beleodaq, Beleodaq®, PXD 101, PXD-101, PXD101

Other1 trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3

Sacramento, California1 trial

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

University of California Davis Comprehensive Cancer Center

Phase 1

South San Francisco, California1 trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals

Phase 3

Bethesda, Maryland1 trial

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center

Phase 2

Salt Lake City, Utah1 trial

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

Huntsman Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.